Gm-Csf
Pediatric Brain Tumor
Gary Archer Ph.D.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
62 Active assets in the Pediatric Brain Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib M.D. Anderson Cancer Center | Phase 2 | BBB |
Temsirolimus M.D. Anderson Cancer Center | Phase 2 | BBB |
Sorafenib National Cancer Institute (NCI) | Phase 2 | BB |
Bxcl501 Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 4 | BB |
Nivolumab InSightec | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Gm-Csf is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →